Venetoclax and hypomethylating agents in acute myeloid leukemia: Mayo Clinic series on 86 patients
Erika Morsia(Marche Polytechnic University), Naseema Gangat(Mayo Clinic in Arizona), Ayalew Tefferi(Mayo Clinic), Maansi Joshi(Mayo Clinic), Mithun Vinod Shah(Mayo Clinic in Arizona), Animesh Pardanani(Mayo Clinic), Joselle Cook(Mayo Clinic), Michelle A. Elliott(Mayo Clinic), Hassan B. Alkhateeb(Mayo Clinic), Mrinal M. Patnaik(Mayo Clinic), Kristen McCullough(Mayo Clinic), Kebede H. Begna(Mayo Clinic), William J. Hogan(Mayo Clinic), Mark R. Litzow(Mayo Clinic in Arizona), Aref Al‐Kali(Mayo Clinic)
Cited by 136
Related Papers
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
|Blood|2009|4.4k
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
|Cancer Cell|2005|3k
International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data
|Blood|2022|2.7k
Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
|New England Journal of Medicine|2012|1.9k